The 2018-2019 year has been a year of transition for Anatara Lifesciences (ASX:ANR), having commenced the year with a clear focus on successfully evolving into a human health company, through the pursuit of the burgeoning gastrointestinal health market.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30th June 2019.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the Monsoon Communications Twilight Investor Briefing, yesterday evening, in Melbourne.
Anatara Lifesciences Ltd's (ASX:ANR) CEO, Steve Lydeamore will be presenting to investors at a Monsoon Communications Twilight Investor Briefing event in Melbourne next week. Investors interested in attending this presentation are invited to reach out.
Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets (known as scour), with potential application in other livestock animals, aquaculture and companion animals.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the 15th Bioshares Biotech Summit, held in Queenstown, New Zealand, 26th to 27th July 2019.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th June 2019. The Company's cash plus term deposits at the end of the quarter stood at $5.4m. On 30th June 2019, the Company had cash at bank of $1,360,086 and $4,050,000 in term deposits. Expenditure during the quarter was in line with forecast.
